<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01297842</url>
  </required_header>
  <id_info>
    <org_study_id>SirirajCEU 54-001</org_study_id>
    <nct_id>NCT01297842</nct_id>
  </id_info>
  <brief_title>Ertapenem Versus Meropenem/Imipenem for ESBL+ Gram-negative Infections</brief_title>
  <official_title>An Open-label, Randomized Equivalence Trial and Cost-effectiveness Analysis of Ertapenem Versus Other Carbapenems for Treatment of Extended -Spectrum Beta-Lactamase (ESBL)-Producing Gram-negative Bacterial Infections</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mahidol University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Mahidol University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Adult patients with ESBL-producing Gram negative infections are randomized to receive
      ertapenem or meropenem/imipenem. Clinical and microbiological responses between both groups
      are compared.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Ertapenem is active against ESBL-producing Gram negative bacteria. This study is conducted to
      determine if ertapenem is effective against ESBL-producing Gram negative infections similar
      to meropenem/imipenem.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>May 2011</start_date>
  <completion_date type="Anticipated">August 2013</completion_date>
  <primary_completion_date type="Anticipated">April 2013</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of subjects with cure or improvement</measure>
    <time_frame>14 days</time_frame>
    <description>Cure Improvement Persistence Death from Infection</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of subjects with eradication of the causative bacteria</measure>
    <time_frame>14 days</time_frame>
    <description>Eradication Persistence Superinfection</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Drug Safety</condition>
  <arm_group>
    <arm_group_label>Ertapenem</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Ertapenem 1 gram per day for 7 to 14 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Meropenem or Imipenem</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Meropenem or Imipenem o.5 or 1 gram 3 to 4 times a day for 7 to 14 days</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ertapenem</intervention_name>
    <description>Ertapenem 1 gram per day for 7 to 14 days</description>
    <arm_group_label>Ertapenem</arm_group_label>
    <other_name>Invanz</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Meropenem or Imipenem</intervention_name>
    <description>Meropenem or Imipenem 0.5 to 1 gram 3 to 4 times per day for 7 to 14 days</description>
    <arm_group_label>Meropenem or Imipenem</arm_group_label>
    <other_name>Meronem</other_name>
    <other_name>Tienam</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Hospitalized patients aged &gt;18 years with documented ESBL +ve GNB infection

          -  Receive meropenem or imipenem/cilastatin as empiric antibiotic therapy

        Exclusion Criteria:

          -  Having been treated with meropenem or imipenem/cilastatin for longer than 72 hours

          -  Have active P. aeruginosa co-infection

          -  Pregnancy or breast feeding

          -  Allergy to carbapenems
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Visanu Thamlikitkul, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Siriraj Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Visanu Thamlikitkul, MD</last_name>
    <phone>6624125994</phone>
    <email>sivth@mahidol.ac.th</email>
  </overall_contact>
  <location>
    <facility>
      <name>Siriraj Hospital</name>
      <address>
        <city>Bangkok</city>
        <zip>10700</zip>
        <country>Thailand</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Visanu Thamlikitkul, MD</last_name>
      <phone>662-412-5994</phone>
      <email>sivth@mahidol.ac.th</email>
    </contact>
    <investigator>
      <last_name>Visanu Thamlikitkul, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Thailand</country>
  </location_countries>
  <verification_date>December 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 14, 2011</study_first_submitted>
  <study_first_submitted_qc>February 16, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 17, 2011</study_first_posted>
  <last_update_submitted>December 29, 2011</last_update_submitted>
  <last_update_submitted_qc>December 29, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 2, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Mahidol University</investigator_affiliation>
    <investigator_full_name>Visanu Thamlikitkul</investigator_full_name>
    <investigator_title>Division of Infectious Diseases and tropical medicine, Department of medicine, Faculty of Medicine Siriraj Hospital.</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gram-Negative Bacterial Infections</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Meropenem</mesh_term>
    <mesh_term>Thienamycins</mesh_term>
    <mesh_term>Imipenem</mesh_term>
    <mesh_term>Ertapenem</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

